Abstract
Connexin 43 (Cx43), the principal gap junction protein in vascular smooth muscle cells (VSMCs), regulates movement of ions and other signaling molecules through gap junction intercellular communication (GJIC) and plays important roles in maintaining normal vessel function; however, many of the signaling mechanisms controlling Cx43 in VSMCs are not clearly described. The goal of this study was to investigate mechanisms of Cx43 regulation with respect to VSMC proliferation. Treatment of rat primary VSMCs with the cAMP analog 8Br-cAMP, the soluble guanylate cyclase (sGC) stimulator BAY 41-2272 (BAY), or the Cx inducer diallyl disulfide (DADS) significantly reduced proliferation after 72 h compared with vehicle controls. Bromodeoxyuridine uptake revealed reduction (p < 0.05) in DNA synthesis after 6 h and flow cytometry showed reduced (40%) S-phase cell numbers after 16 h in DADS-treated cells compared with vehicle controls. Cx43 expression significantly increased after 270 min treatment with 8Br-cAMP, 8Br-cGMP, BAY or DADS. Inhibition of PKA, PKG or PKC reversed 8Br-cAMP-stimulated increases in Cx43 expression, whereas only PKG or PKC inhibition reversed 8Br-cGMP- and BAY-stimulated increases in total Cx43. Interestingly, stimulation of Cx43 expression by DADS was not dependent on PKA, PKG or PKC. Using fluorescence recovery after photobleaching, only 8Br-cAMP or DADS increased GJIC with 8Br-cAMP mediated by PKC and DADS mediated by PKG. Further, DADS significantly increased phosphorylation at MAPK-sensitive Serine (Ser)255 and Ser279, the cell cycle regulatory kinase-sensitive Ser262 and PKC-sensitive Ser368 after 30 min while 8Br-cAMP significantly increased phosphorylation only at Ser279 compared with controls. This study demonstrates that 8Br-cAMP- and DADS-enhanced GJIC rather than Cx43 expression and/or phosphorylation plays important roles in the regulation of VSMC proliferation and provides new insights into the growth-regulatory capacities of Cx43 in VSM.
Keywords: vascular smooth muscle cells, Cx43, cAMP, cGMP, protein kinases
Introduction
Coordination of vascular cell responses is necessary for normal vessel function and is largely regulated by ionic intercellular coupling via gap junctions. Gap junctional intercellular communication (GJIC) uniquely allows the cellular exchange of metabolites, ions, and other small molecules such as second messengers which play important roles in transverse and longitudinal signaling in the vascular bed (Coutinho et al., 2003; Liao et al., 2007; Chadjichristos et al., 2008). Intercellular communication through gap junctions in cardiovascular tissues is involved in diverse processes such as determination of vasomotor tone, cell differentiation, growth control, embryonic development, and coordination of contraction of cardiac muscle cells (Yamasaki et al., 1996; Liao et al., 2007; Chadjichristos et al., 2008). Bidirectional cellular communication conducted by gap junctions is also believed to be integral in acetylcholine-induced vasoconstriction (Figueroa and Duling, 2009) and in maintaining cell quiescence (Zhang et al., 2003).
Gap junctions are comprised of connexin (Cx) proteins (Kumar and Gilula, 1996; Yamasaki and Naus, 1996) and serve as transmembrane channels that act as intercellular conduits for GJIC. In the vasculature, gap junction channels are formed from combinations of one or more of the four connexin protein isomers: Cx37, 40, 43, and/or 45 (Little et al., 1995; Evans and Martin, 2002; Johnstone et al., 2009) and the predominant connexin in vascular smooth muscle (VSM) is Cx43 (Haefliger et al., 2004; Saitongdee et al., 2004; Isakson et al., 2006). Reduction in Cx43 protein expression and functionality have been associated with enhanced VSM cell (VSMC) proliferation and differentiation in atherosclerotic plaques (Kwak et al., 2002); however, the mechanisms for altered Cx43 expression in atherogenesis have not been well described but are thought to contribute to its disease progression. Studies have demonstrated that loss of Cx43 (Solan et al., 2003; Shao et al., 2005; Norris et al., 2008) or altered Cx phosphorylation status (Dang et al., 2006; Solan and Lampe, 2007) is sufficient to enhance the proliferative capacity of cells. Cx43 may undergo multiple phosphorylation events and at least five phosphorylated Serines (Ser) have been detected on Cx43 isolated from non-stimulated cells and several more have been identified under growth factor- or kinase-stimulated conditions (Lampe and Lau, 2004). These phosphorylation events correlate with changes in assembly and degradation of Cx43 gap junction channels and thus could play important roles in regulating GJIC (Cooper et al., 2000), yet their physiological significance particularly in VSM remains largely uncharacterized.
Cyclic AMP (cAMP) and cyclic GMP (cGMP) are ubiquitous second messengers that are involved in a variety of functions during vascular homeostasis and following injury or disease; however, the exact roles for cAMP and cGMP in the regulation of connexins and GJIC are not clear. It has been reported that activation of the nitric oxide (NO)/cGMP system induces Cx43 expression and increases GJIC (Yao et al., 2005), yet full characterization of cAMP and cGMP and their physiological influence on Cx43 expression and functionality in VSM is warranted.
The overall objective of the present study was to determine the relation between Cx43 expression, functionality, and phosphorylation states with respect to cell proliferation in VSMCs in the presence of cAMP and cGMP analogs and in comparison to the indirect soluble guanylate cyclase (sGC) stimulator BAY 41-2272 (BAY) and the Cx43 stimulant and garlic compound diallyl disulfide (DADS). In summary, results from this study show that an increase in Cx43-mediated GJIC is essential for control of proliferation in primary VSMCs and that enhanced expression and/or differential phosphorylation of Cx43 alone do not serve as effective growth regulators. Moreover, evidence is presented supporting roles for 8Br-cAMPand DADS and physiologically effective agents in the control of VSM growth.
Materials and Methods
Isolation and culture of rat primary VSMCs
This study abided by the guidelines of the East Carolina University Animal Care and Use Committee and conformed to the Guide for the Care and Use of Laboratory Animals (US NIH, Pub. No. 85–23, rev. 1996). Male Sprague-Dawley rats (100–125 g) were anesthetized [ketamine (90 mg/ml), xylazine (10 mg/ml; 1 ml/kg, i.p.)] and euthanized by pneumothorax and exsanguination. Vascular SMCs (VSMCs) were harvested from the thoracic aorta and isolated by collagenase and elastase digestion as described (Durante et al., 1993; Liu et al., 2009). Cells were cultured serially (passage 1–6) in Dulbecco’s minimum essential media (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM l-glutamine, sodium pyruvate, 5 mM HEPES, and Primocin (100 mg/l) in the presence of 95% air/5% CO2.
Treatments
Unless otherwise stated, VSMCs were treated with 8Br-cAMP or 8Br-cGMP (Adderley et al., 2012) at 100 μM, BAY 41-2272 at 100 nM, or DADS at 50 μM. For treatments involving kinase inhibition, VSMC were treated with PKI (10 μM; Schlegel and Waschke, 2009) for inhibition of PKA, DT2 (YGRKKRRQRRRPP-LRKKKKKH-amide; 10 μM; Dostmann et al., 2002; Dey et al., 2005) to inhibit PKG, or calphostin-C (CalC; 100 nM; Touyz and Schiffrin, 1997) to inhibit PKC for 15 min prior to treatment with vehicle, 8Br-cAMP, 8Br-cGMP, BAY, or DADS.
MTT assay
Vascular smooth muscle cells were plated onto 96-well plates at 21,000 cells/well and treated with 8Br-cAMP, 8Br-cGMP, BAY, or DADS. After 12 or 72 h 2,5-diphenyltetrazolium bromide (MTT) solution was added to the media and the cells incubated for 3 h. The MTT-containing media was discarded and the cells were gently washed with PBS. Formazan formed within the cells was then dissolved in acetic-isopropanol and the plate was read at 570 nm with correction at 750 nm. The optical density (OD) of the treatments was normalized to vehicle controls.
Hemocytometry and neutral red uptake
Hemocytometry was performed after 72 h to obtain viable cell numbers and Neutral Red Uptake was performed after 12 h as an estimate of cellular toxicity per established protocols (Mendelev et al., 2009; Joshi et al., 2011).
BrdU uptake
The rate of DNA synthesis was measured with 5-bromo-2′-deoxyuridine (BrdU) labeling (Giordano et al., 2008) with detection (Detection Kit II, Roche Diagnostics Corporation, Indianapolis, IN, USA) following manufacturer’s instructions. Briefly, cells were plated onto 96-well plates at 21,000 cells/well. After quiescing overnight, cells were treated with 8Br-cAMP, 8Br-cGMP, BAY, or DADS for 2 h followed by BrdU treatment for 4 h. Cells were fixed and incubated in the presence of the anti-BrdU antibody for 1 h, after which the antibody was removed and the detection reagent added. The plate was read on a spectrophotometer at 370 nm with a reference at 492 nm. The OD of the treatments was normalized to vehicle controls.
Cell cycle analysis
Flow cytometric cell cycle analysis was performed as described (Joshi et al., 2011). Briefly, VSMCs were seeded in 24-well plates (100,000 cells/well) and after adherence were quiesced overnight in DMEM containing 0.2% FBS. Cells were treated with vehicle, 8Br-cAMP or DADS for 16 h. The cells were trypsinized, fixed in cold ethanol, stained with propidium iodide, and subjected to flow cytometry (Accuri C6).
In-cell western blotting
The effects of 8Br-cAMP, 8Br-cGMP, BAY, or DADS alone or in the presence of PKA, PKG, or PKC inhibitors PKI, DT2, or CalC on Cx43 expression in VSMCs were studied using the in-cell Western (ICW) method (Chen et al., 2005). Primary VSMCs were seeded in black 96-well flat bottom plates at 21,000 cells/well and following attachment were treated with respective agents for 30 or 270 min or 24 h. For inhibitor studies, VSMCs were pretreated for 15 min with PKI (10 μM), DT2 (10 μM), or CalC (100 nM) followed by treatment with 8Br-cAMP, 8Br-cGMP, BAY, or DADS for 270 min. Reactions were stopped by replacing media with 4% phosphate-buffered formalin. Fixed cells were permeabilized with 0.1% Triton, blocked, and incubated with IR-tagged rabbit antibodies against Cx43 or the phosphorylated forms of Cx43 at Serines 255, 262, 279, and 368 (Cell Signaling) along with mouse α-tubulin (Sigma) as the housekeeping control at 1:500 dilutions overnight at 4°C. Cells were washed with PBS-Tween and incubated with anti-rabbit IR 800 and anti-mouse IR 680 (Rockland) secondary antibodies for 1 h. The proteins were quantified by fluorescence (LiCor Odyssey) and normalized with respect to α-tubulin within each well. All treatments were normalized to vehicle control.
Western blotting
Western blotting was performed on whole cell lysates as previously described (Mendelev et al., 2009) with slight modifications. After treatment with 8Br-cAMP, 8Br-cGMP, BAY, or DADS for 270 min, cells were collected, homogenized, sonicated, boiled, and SDS-PAGE was performed using 20 μg protein samples. The separated blots were transferred to nitrocellulose membrane, blocked, and incubated overnight at 4°C with IR-tagged antibodies against rabbit Cx43 protein (Millipore) and mouse α-tubulin (Sigma) at 1:3000 dilutions. After washes the membranes were incubated in anti-rabbit IR800 and anti-mouse IR680 secondary antibodies (Rockland; 1:3000) for 1 h at room temperature. Blots were washed and proteins were quantified by fluorescence densitometry (Li-Cor Odyssey) and normalized with respect to α-tubulin.
Gap junction communication
Gap junction-mediated cell–cell communication was measured using a fluorescence recovery after photobleaching (FRAP) assay as described (Goodwin and Kenworthy, 2005; Shen et al., 2010) with slight modifications. In this assay, recovery of fluorescence in a previously bleached cell is the result of influx of native dye from neighboring cells via gap junctions (Wade et al., 1986; Muller-Borer et al., 2004; Shen et al., 2010). Thus, the FRAP assay is a direct measure of gap junction permeability and conductance and is a reliable measure of GJIC functionality. Moreover, FRAP is non-invasive, highly sensitive, and faster compared to more traditional GJIC approaches such as microinjection and dye transfer (Shen et al., 2010). Lastly, in this study FRAP measurements were performed after 15-min treatment, a physiologically relevant time point for the measurement of acute changes in gap junction function. Briefly, FRAP was performed using a laser scanning confocal microscope (Leica TCS-SP, Heidelberg, Germany), mounted on a Leica inverted microscope with a 63× water objective. Primary VSMCs were seeded (∼35,000 cells) and grown to confluence on glass coverslips. For the loading of Calcein AM (Invitrogen), cells were washed with warm PBS and incubated in phenol-free DMEM containing Calcein AM (1 μM) for 45 min, washed with warm PBS and incubated in 10% FBS in DMEM. Cells were treated for 15 min with either 8Br-cAMP, 8Br-cGMP, BAY, or DADS and subjected to FRAP. In the inhibitor study with 8Br-cAMP and DADS, 15 min treatment of the respective PKA, PKG, and PKC inhibitors PKI (10 μM), DT2 (10 μM), or CalC (100 nM) was followed by treatment with 8Br-cAMP or DADS. Individual cells connected with at least four cells on all the sides were selected for photobleaching. Calcein AM (Invitrogen Corp, Carlsbad, CA, USA) was excited by a high intensity argon laser pulse at 488 nm to bleach intracellular Calcein in selected cells and captured through grating at 530/30 nm. The bleached cell was then monitored, and images were acquired continuously every 10 s for the initial minute, followed by 30 second intervals for 2 minutes and 1 minute intervals for another 2 minutes. GJIC between a cell and its neighbors was quantified by measuring the initial rate and percentage of fluorescence recovery. Non-photobleached cells were monitored as controls for spontaneous photobleaching. The rate of fluorescence recovery was estimated using the Zen (2009) software (Carl Zeiss) and the initial recovery rate constants were compared between the treated and vehicle controls. All treatments were normalized to vehicle control and expressed as percentage of vehicle controls.
Statistical analyses
Data were analyzed using Microsoft Excel 2007 and Sigma Plot 11 (SPSS, Inc.). Comparisons between treatment groups were made using one-way analysis of variance (ANOVA) and a multiple comparison Newman–Keuls post hoc test or Student’s t-test as indicated. All data are presented as mean ± SEM. A p-value of <0.05 is considered statistically significant for all comparisons.
Results
VSMC growth
Growth of VSMCs was assessed through use of the MTT assay and hemocytometric cell counts after 72 h, flow cytometry after 16 h, and BrdU incorporation after 6 h. Mitochondrial dysfunction and cellular toxicity from all treatments were also evaluated after 12 h. Using the MTT assay after 72 h, 8Br-cAMP (100 μM), BAY (100 nM), or DADS (50 μM) significantly reduced VSMC proliferation compared with vehicle controls; however, 8Br-cGMP was without effect (Figure 1A). In agreement, hemocytometry after 72 h also revealed significant reduction in cell numbers following treatment with 8Br-cAMP (100 μM) or BAY (100 nM), and a non-significant trend (∼20% reduction; p = 0.06) was observed for the DADS treatment group (Figure 1B). The MTT assay performed after 12 h indicated no observable mitochondrial dysfunction in any cohort (Figure 1C). Similarly, Neutral Red Uptake after 12 h showed no significant differences between treatment and vehicle control groups (data not shown).
Following BrdU uptake for 6 h, DADS (50 μM) significantly reduced (20%) the rate of DNA synthesis compared with vehicle controls (Figure 2), yet 8Br-cAMP, 8Br-cGMP, or BAY showed no effects on DNA synthesis at this time point.
Flow cytometry performed as a measure of cell cycle progression showed that DADS significantly reduced the number of cells in the S-phase (∼40%) compared with vehicle controls after 16 h, while 8Br-cAMP caused non-significant decreases in cell numbers in the S and G2/M phases and a non-significant increase in G0/G1 cells (Figure 3).
Cx43 expression
Using both IR-based Western and ICW analyses, incubation of rat primary VSMCs with 8Br-cAMP or 8Br-cGMP (100 μM), BAY (100 nM), or DADS (50 μM) significantly increased total Cx43 expression (normalized to α-tubulin) compared with vehicle controls after 270 min (Figure 4). Figure 4A shows densitometry results following ICW, and all agents increased total Cx43 by 20–25%. Interestingly, after 24 h only DADS significantly increased total Cx43 expression (Figure 4B). Of note, reducing the incubation period to 30 min in the presence of the four compounds showed no changes in Cx43 expression (data not shown). Using traditional, IR-Western blotting, the same trends were observed for increased total Cx43 expression (data not shown), yet the extent of increases was much higher than that observed with ICW. A representative IR-Western blot for total Cx43 expression is shown in Figure 4C. Figure 4D shows a representative photomicrograph of confluent VSMCs following immunocytochemical staining for Cx43 which shows punctate presence of gap junctions predominantly at cell-to-cell contacts (indicated by arrows).
Effects of kinase inhibition on stimulated Cx43 expression
Kinase regulation of Cx43 expression in the presence of 8Br-cAMP, 8Br-cGMP, BAY, or DADS was tested using selective kinase blockade and evaluated through ICW analysis. Respective inhibition of PKA, PKG, and PKC by PKI, DT-2, and CalC significantly reversed the stimulatory effects of 8Br-cAMP on total Cx43 expression (Figure 5A). In comparison, only the inhibition of PKG and PKC (by DT-2 and CalC, respectively) reversed the stimulation of Cx43 expression induced by both the direct-activating 8Br-cGMP (Figure 5B) and the indirect sGC stimulator BAY (Figure 5C). Inhibition of any of the kinases, PKA, PKG, or PKC, did not have any effect on DADS-induced stimulation of Cx43 expression (Figure 5D). Lastly, each inhibitor alone failed to alter basal (vehicle-treated) total Cx43 expression (Figure 5E). A summary of results from the kinase inhibitor studies on Cx43 expression is shown in Table 1.
Table 1.
Kinase inhibitors |
||||
---|---|---|---|---|
Treatment | Total Cx43 expression | w/PKI (PKA inhibition) | w/DT-2 (PKG inhibition) | w/CalC (PKC inhibition) |
8Br-cAMP | ↑ | ↓ | ↓ | ↓ |
8Br-cGMP | ↑ | – | ↓ | ↓ |
BAY 41-2272 | ↑ | – | ↓ | ↓ |
DADS | ↑ | – | – | – |
Cell-to-cell communication
Using FRAP as a measure of GJIC and gap junction functionality, incubating cells for 15 min in the presence of 8Br-cAMP increased GJIC by 50% and in the presence of DADS by 80% over vehicle controls while the presence of 8Br-cGMP or BAY had no effect (Figure 6A). After 270 min 8Br-cAMP or DADS failed to enhance GJIC (data not shown). Representative photomicrographs of adherent VSMCs subjected to FRAP analysis are shown (Figures 6B–E) with the photobleached cell of interest outlined. Figure 6B shows a cell immediately prior to photobleaching; Figure 6C shows that cell immediately after photobleaching; Figure 6D shows the cell 2.5 min after photobleaching and some degree of fluorescent recovery is apparent; Figure 6E shows the cell 4.5 min after photobleaching at the conclusion of fluorescence recovery.
To examine kinase involvement in the acute stimulation of GJIC by 8Br-cAMP or DADS, FRAP was studied following select kinase inhibition in the presence of 8Br-cAMP or DADS. GJIC stimulated by 8Br-cAMP was reversed by PKC inhibition alone (Figure 7A), whereas GJIC stimulated by DADS was markedly subdued (p = 0.06) by DT-2-mediated inhibition of PKG alone (Figure 7B).
Cx43 phosphorylation
Site-specific phosphorylation of Cx43 was studied at four sites known to be sensitive to kinase activation: Ser255 and Ser279 (MAPK-specific), Ser262 (p34cdc2 kinase-specific), and Ser368 (PKC-specific). In the presence of 8Br-cAMP, phosphorylation of Cx43 increased (∼20–30%) at both MAPK-sensitive sites (Ser255 and Ser279) compared with vehicle controls, reaching statistical significance at the Ser279 site (Figure 8A). In comparison, DADS significantly increased (∼30%) phosphorylation at MAPK-sensitive Ser255 and Ser279, the p34cdc2-sensitive Ser262, and the PKC-sensitive Ser368 (Figure 8B).
Discussion
Accumulating evidence indicates a regulatory role for connexins and gap junction communication in a variety of vascular pathologies including hypertension (Figueroa et al., 2006; Brisset et al., 2009) ischemia/reperfusion injury (Jara et al., 1995), atherosclerosis (Blackburn et al., 1995; Polacek et al., 1997; Yeh et al., 1997), and the growth response to vascular injury (Yeh et al., 1997; Kurjiaka et al., 1998; Brisset et al., 2009). Mechanistically, a variety of controlling elements have been examined for Cx (Figueroa and Duling, 2009), yet few reports have investigated a role for cyclic nucleotides in the control of Cx43 expression and functionality with respect to VSM growth. Hence, this study aimed to understand the physiological relevance of Cx43 regulation by cyclic nucleotide signaling in VSM growth. Using rat primary VSMCs, the cyclic nucleotide analog 8Br-cAMP and the garlic-derived diallyl compound DADS reduced proliferation and DNA synthesis and increased Cx43 expression and functionality, establishing a direct link between VSMC proliferation and Cx43. It was also observed that distinct protein kinase signals have capacity to regulate Cx43 expression and functionality that are modulated by 8Br-cAMP and DADS. In summary, this study provides direct evidence for the mechanistic basis of gap junctional communication in the regulation of VSMC proliferation.
In this study both metabolically stable, direct-activating cyclic nucleotide analogs and indirect sGC stimulation were used to induce cyclic nucleotide signaling. Using 8Br-cAMP and 8Br-cGMP, after a 72-h exposure only 8Br-cAMP significantly reduced cell proliferation estimated by the MTT and hemocytometry assays, confirming an earlier report using a different cAMP analog (Indolfi et al., 2000). In the current study it was interesting to note that 8Br-cGMP failed to exert noticeable effects on VSMC growth as earlier studies report anti-proliferative effects by stimulation of cGMP-related pathways (Lincoln et al., 2006) but not by cGMP per se. To complement findings from the proliferation assays, two additional approaches were employed to examine VSMC growth. Bromodeoxyuridine uptake allows study of DNA synthesis whereas flow cytometry explores cell cycle progression. Most reports studying the effects of cGMP on VSMC proliferation involve indirect cGMP stimulation that may have untoward effects such as those mediated by cAMP considering that cGMP-mediated inhibition of PDE3 increases cAMP levels (Maurice and Haslam, 1990). Remarkably, neither 8Br-cAMP nor 8Br-cGMP showed influence on the rate of DNA synthesis estimated by BrdU uptake after 6 h. Nonetheless, using flow cytometry 8Br-cAMP showed insignificant decreases in S-phase and G2/M phase cells with a slight increase in G0/G1 cells after 16 h. The effects on the nuclear mechanisms in the presence of 8Br-cAMP were not evident at the acute time points analyzed; nonetheless, the inhibition of VSMC growth after 72 h was significant confirming earlier reports that elevated cAMP inhibits VSMC proliferation in vitro (Wu et al., 2006).
Recent findings from our lab provide solid evidence that pharmacologic sGC stimulation increases both cAMP and cGMP (Adderley et al., 2012) and inhibits neointimal growth after balloon injury (Joshi et al., 2011). In the current study in comparison to the effects of the cyclic nucleotide analogs, the sGC stimulator BAY 41-2272 (BAY) did not significantly reduce DNA synthesis but reduced VSMC proliferation after 72 h as reported earlier (Joshi et al., 2011). This anti-proliferative effect of BAY was recently suggested to occur through Cdk suppression and elevation of p21 and p27 (Mendelev et al., 2009); however, that study used BAY at 10 μM in commercial A7R5 VSMCs whereas the present study used BAY at 100 nM in primary VSMCs. Additionally, this current study and our recent report (Joshi et al., 2011) attribute decreases in VSMC proliferation induced by BAY to changes in phosphorylation of vasodilator-activated serum phosphoprotein (VASP), a marker of differential kinase activation (Butt et al., 1994), and a critical cytoskeletal and focal adhesion element (Reinhard et al., 2001).
In the current study a significant reduction in VSMC growth and DNA synthesis by DADS was complemented by a decrease in the number of cells in the S-phase, estimated by flow cytometry. The inhibitory effects of DADS on cell growth in other systems have been mostly attributed to an increase in the apoptotic cell populations correlated with depressed p34cdc2 kinase activity (Knowles and Milner, 2000), and at the same time DADS has been reported to be a potent stimulator of Cx43 expression and activity (Huard et al., 2004). DADS has been reported to induce S-phase block in tumorigenic CNE2 cells (Zhang et al., 2006), observed in the present study in VSMCs as well.
Expression of Cx43 has been reported to be regulated by cAMP in thymic epithelial cells (Nihei et al., 2010), but scientific evidence is lacking for the effects of cAMP or cGMP on Cx43 expression and functionality in primary VSM. The present study exclusively used primary VSMCs to study the effects of the brominated cyclic nucleotide analogs and BAY on Cx43 expression/functionality and to investigate the roles of PKA, PKG, and PKC in mediating these events. Both 8Br-cAMP and 8Br-cGMP stimulated total Cx43 protein expression providing direct evidence for the regulation of Cx43 by cyclic nucleotides in VSMCs. These cyclic nucleotide analogs are known to act via kinase pathways. The known inhibitors PKI, DT-2, and CalC were used for respective inhibition of PKA, PKG, and PKC, and inhibition of all the three individual kinases reversed 8Br-cAMP-stimulated Cx43 expression, providing direct evidence for the role of all the three kinases in 8Br-cAMP-mediated stimulation of Cx43 expression. At the same time an involvement of only the PKG and PKC pathways was evident in 8Br-cGMP stimulation of Cx43 expression as only DT-2 and CalC reversed 8Br-cGMP-mediated stimulation of Cx43 expression. This is the first report providing evidence for involvement of cyclic nucleotide-mediated kinase pathways in the regulation of Cx43 expression in primary VSM. In comparison to these direct analogs, the sGC/cGMP stimulator BAY was also observed to stimulate Cx43 expression that was reversed by the inhibition of PKG and PKC, the same kinases that were involved in the stimulation of Cx43 expression by 8Br-cGMP. The diallyl compound DADS is known to stimulate Cx43 in rat liver cells (Huard et al., 2004), and in the current study was found to increase Cx43 expression and conductance in rat primary VSMCs. Interestingly, these effects of DADS on Cx43 expression appear independent of the kinase pathways studied here, namely PKA, PKG, or PKC.
Although 8Br-cAMP, 8Br-cGMP, BAY, and DADS each independently increased Cx43 expression, it was only with 8Br-cAMP and DADS that an increase in GJIC was observed confirming earlier reports (Huard et al., 2004; Nihei et al., 2010). Although 8Br-cGMP has been observed to increase GJIC in other tissues such as the mesangium (Yao et al., 2005), similar effects on GJIC were not observed in the rat primary VSMC in this study. It is important to note that the increased GJIC reported earlier (Yao et al., 2005) in the presence of 8Br-cGMP was in the presence of a very high concentration of analog (500 μM) and observed after a 24-h incubation, whereas in the present study 8Br-cGMP was used at 100 μM for 15 min under more physiologically realistic conditions. A high turnover rate (t1/2 1.5–3.5 h; Laird et al., 1991) has been observed for plasma membrane-localized Cx43. Cx43 also possesses multiple phosphorylation sites (Lampe and Lau, 2000). Thus, the purpose of using a shorter time point was to avoid potential changes in Cx43 expression levels and to investigate if rapid phosphorylation of Cx43 coincided with changes in GJIC. Furthermore, short-term incubation (30 min) in the presence of 8Br-cAMP, 8Br-cGMP, BAY, or DADS had no effects on the Cx43 expression levels (data not shown). A number of reports have shown that increased cAMP increases Cx43 expression, functionality, and phosphorylation (Lampe and Lau, 2004) and specifically the increase in Cx43 expression appears to be mediated by PKA (Paulson et al., 2000) in hepatoma cells and it has only recently been reported that the cAMP/PKA pathway regulates GJIC in mouse embryonic stem cells (Yun et al., 2012). The stimulation of GJIC by 8Br-cAMP observed in this study was reversed by the PKC inhibitor CalC, and it was surprising to note that neither PKA nor PKG had any role in regulating 8Br-cAMP-stimulated GJIC. In rat primary VSMC crosstalk between the different kinases has been reported (Adderley et al., 2012; Joshi et al., 2011). Moreover, the different kinases may play varying roles in regulating Cx43 expression/functionality depending on their tissue/organ specificity and perhaps precise localization within the cellular milieu (Adderley et al., 2012).
In this effort the sGC modulator BAY did not exert noticeable effects on GJIC in rat primary VSMC. This is the first report studying the influence of BAY on Cx43 expression and functionality, and although BAY has been reported to inhibit VSMC proliferation through cGMP-dependent pathways (Mendelev et al., 2009) it does not seem to be dependent upon a functional Cx43. It could be possible, however, that the BAY-stimulated increase in Cx43 expression may have delayed effects on VSMC proliferation that were not evident at the time points observed in this study.
The diallyl garlic compound DADS has been reported to be cancer chomopreventive in a number of studies (Schaffer et al., 1996; Knowles and Milner, 2000; Arunkumar et al., 2006) and an important characteristic of DADS is its ability to stimulate Cx43 expression and GJIC (Huard et al., 2004). There is increasing evidence that GJIC alteration is involved in tumor cell development (Trosko and Ruch, 1998), and most studies using DADS have been performed on phenotypically modified or tumorigenic cells. This is the first report characterizing the effects of DADS on VSMC Cx43 with respect to proliferation, and data reveal that DADS stimulates acute GJIC. The shorter treatment time used in this study (15 min) is important as no changes in Cx43 protein expression were detected even after 30-min exposure, and thus these findings signify direct, translation-independent activation of Cx43 leading to the opening of gap junction channels and promoting GJIC. The inhibition of PKG by DT-2 reversed DADS-promoted GJIC in the rat primary VSMCs which was not reversed by either PKA or PKC inhibition. This observation indicates involvement of the PKG pathway in DADS stimulation, and in comparison with the role for PKC in the activation of GJIC by 8Br-cAMP, clearly supports the notion of crosstalk between the kinases that appears to be tissue- and function-specific. The study also highlights the fact that the functionality of gap junctions plays a more important role in regulating the proliferation of VSMC than does simple expression of the gap junction proteins.
Considering the potential involvement of site-specific Cx43 phosphorylation in regulating GJIC that may control cell proliferation, phosphorylation of Cx43 was studied at the MAPK-sensitive sites Ser255 and Ser279, the cell cycle regulatory p34cdc2-sensitive Ser262, and PKC-sensitive Ser368. Although both 8Br-cAMP and DADS had similar effects on VSMC growth and Cx43 expression and functionality, they have different site-specific Cx43 phosphorylation profiles. Using the ICW technique that is preferred for evaluation of phosphorylated residues, 8Br-cAMP stimulated Cx43 phosphorylation at only the MAPK-sensitive Ser255 and Ser279 sites while DADS stimulated phosphorylation of Cx43 at multiple sites including Ser255 and Ser279, Ser262 and Ser368. Studies have demonstrated alteration in the proliferative state of a cell with a loss of Cx43 (Solan et al., 2003; Shao et al., 2005; Norris et al., 2008) or its altered phosphorylation status (Dang et al., 2006; Solan and Lampe, 2007). Changes in Cx43 phosphorylation and gap junctional communication have also been observed as cells proceed through the cell cycle (Koo et al., 1997; Xie et al., 1997; Kanemitsu et al., 1998; Lampe et al., 1998; Bittman and LoTurco, 1999; Solan et al., 2003), indicating that GJIC and Cx43 phosphorylation are tightly regulated and linked during cell cycle. It is important to note that the role of Cx43 phosphorylation may differ considerably among cell types, stages of cell cycle, growth factor milieu and extracellular matrix interactions, and given its short t1/2 and rapid turnover, its phosphorylative capacity must be closely regulated. Although a loss of GJIC has been reported in WB-F344 rat liver epithelial cells (Ruch et al., 2001) and in the IAR6.1 rat liver epithelial cell (Rivedal and Opsahl, 2001) line after TPA treatment along with Cx43 phosphorylation at the MAPK active sites, Ser255 and Ser279, a similar effect was not seen in the rat primary VSMC after 8Br-cAMP and DADS. In fact, increased phosphorylation of Cx43 at Ser255 and Ser279, MAPK-sensitive sites, correlated with reduced VSMC growth and improved GJIC. Ser262 is a p34cdc2-sensitive phosphorylation site that has been reported to be involved in cell division (Laird, 2005). Following phosphorylation of Cx43 at Ser262 by p34cdc2 protein kinase, a loss of gap junction coupling was observed in Rat1 and human endothelial cells (Lampe et al., 1998). Conversely, in this study in the presence of DADS an increase in Cx43 phosphorylation at Ser262 and GJIC in rat primary VSMC was observed with a decrease in proliferation. These differences can be attributed to unique cellular systems and treatment times, and most importantly, the role of Cx43 phosphorylation may be entirely cell-or tissue-specific that may also depend on the stages of cell growth.
Phosphorylation of Cx43 on Ser368 is mediated by PKC, and earlier reports using rat epithelial T51B cells strongly suggest that PKC directly phosphorylates Cx43 on Ser368 in vivo that contributes to a decrease in intercellular communication (Lampe et al., 2000) and that promotes carcinogenesis (Berthoud et al., 1992). These findings have served as the basis for the hypothesis that reduced cell–cell communication is a critical step in multistage carcinogenesis. The focus of the present study however was growth of normal VSMC and not modified or cancerous cells. Contrary to the earlier report (Lampe et al., 2000), in neonatal rat cardiomyocytes activation of PKC has been reported to cause an increase in junctional conductance (Kwak et al., 1995). The reason for these differences is not yet explained. In the present study GJIC stimulated by 8Br-cAMP was mediated by PKC, while that by DADS appeared to be mediated by PKG. Although 8Br-cAMP did not have any effects on the PKC-sensitive phosphorylation site Ser368 on Cx43, DADS significantly increased phosphorylation at this site with a decrease in VSMC growth, and possibly as shown earlier in the cardiomyocytes (Kwak et al., 1995; Kwak and Jongsma, 1996) the Cx43 in the cardiovascular system may behave differently than in other cell/tissue types.
It should be noted that the primary cells used in this study were derived from thoracic aorta. VSMCs of both resistance and conduit arteries express predominantly Cx43 and Cx45 (Little et al., 1995), and the expression of connexin proteins has been reported to vary particularly in arterioles and small arteries (Schmidt et al., 2008). In addition to this potential vascular heterogeneity among connexin isotypes, it is important to note that connexins in the intimal endothelium and adjacent medial wall are critical in the regulation of gross vessel function. Vasoconstrictor and vasodilatory signals travel rapidly along the vessel network due to the conduction of signals between endothelial and smooth muscle cells (Beny and Connat, 1992), and these occur through gap junctions. The spread of conducted dilations which travel large distances along the vessel are facilitated more by the endothelium, whereas conducted constrictions rely primarily on the smooth muscle. Even though the anatomical characteristics of endothelial cells may provide a more efficient pathway to coordinate vascular behavior (Haas and Duling, 1997), in this study the focus was on connexin physiology of medial wall-derived VSMCs.
It should also be noted that for many of the endpoints analyzed in this study, the overall changes generally ranged between 20 and 40% (with exceptions with the GJIC and inhibitor studies which demonstrated larger effects), and this may raise concerns over their physiological relevance. In comparison, the original characterization of DADS as an inducer of both Cx43 expression and functionality (Huard et al., 2004) reported increases in GJIC between 10 and 30% after 8-h treatment with DADS and 50% after 24 h, agreeing closely with observations in the current study. Thus, in comparison with this original report using DADS as a stimulatory agonist, in the current study the observed changes are considered highly significant and physiologically relevant.
In summary, this study demonstrates a critical role of Cx43 in growth of primary VSM and supports a direct correlation between proliferation and Cx43 expression and gap junction communication. It is important to note that increased expression alone may not lead to increased gap junction communication, and that opening of the channels with functional conductance is the rate-limiting step in cell–cell communication. In this study Cx43-mediated GJIC was found to operate independently of site-specific Cx43 phosphorylation, demonstrating that the role of Cx43 phosphorylation may be mostly dependent on the type of cell/tissue. These findings may open new avenues for further understanding the factors that regulate VSMC growth.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This study was supported by the ECU Undergraduate Research and Creative Activity Award (DNM), National Institutes of Health National Heart, Lung, and Blood Institute Grant R01-HL081720 and NIH American Recovery and Reinvestment Act (2009) Grant R01-HL081720-03S2. We thank Jonathan Clay Fox for providing technical assistance cell culture and Shaquria P. Adderley, Ph.D., Brody School of Medicine, East Carolina University, Greenville, NC for valuable discussions related to this work.
References
- Adderley S. P., Joshi C. N., Martin D. N., Tulis D. A. (2012). Phosphodiesterases regulate BAY 41-2272-induced VASP phosphorylation in vascular smooth muscle cells. Front. Pharmacol. 3:10 10.3389/fphar.2012.00010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Arunkumar A., Vijayababu M. R., Venkataraman P., Senthilkumar K., Arunakaran J. (2006). Chemoprevention of rat prostate carcinogenesis by diallyl disulfide, an organosulfur compound of garlic. Biol. Pharm. Bull. 29, 375–379 10.1248/bpb.29.375 [DOI] [PubMed] [Google Scholar]
- Beny J. L., Connat J. L. (1992). An electron-microscopic study of smooth muscle cell dye coupling in the pig coronary arteries. Role of gap junctions. Circ. Res. 70, 49–55 10.1161/01.RES.70.1.49 [DOI] [PubMed] [Google Scholar]
- Berthoud V. M., Ledbetter M. L. S., Hertzberg E. L., Saez J. C. (1992). Connexin43 in MDCK cells: Regulation by a tumor-promoting phorbol ester and calcium. Eur. J. Cell Biol. 57, 40–50 [PubMed] [Google Scholar]
- Bittman K. S., LoTurco J. J. (1999). Differential regulation of connexin 26 and 43 in murine neocortical precursors. Cereb. Cortex 9, 188–195 10.1093/cercor/9.2.188 [DOI] [PubMed] [Google Scholar]
- Blackburn J. P., Peters N. S., Yeh H. I., Rothery S., Green C. R., Severs N. J. (1995). Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15, 1219–1228 10.1161/01.ATV.15.8.1219 [DOI] [PubMed] [Google Scholar]
- Brisset A. C., Isakson B. E., Kwak B. R. (2009). Connexins in vascular physiology and pathology. Antioxid. Redox Signal. 11, 267–282 10.1089/ars.2008.2115 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Butt E., Abel K., Krieger M., Palm D., Hoppe V., Hoppe J., Walter U. (1994). cAMP and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem. 269, 14509–14517 [PubMed] [Google Scholar]
- Chadjichristos C. E., Morel S., Derouette J. P., Sutter E., Roth I., Brisset A. C., Bochaton-Piallat M. L., Kwak B. R. (2008). Targeting connexin 43 prevents platelet-derived growth factor-BB-induced phenotypic change in porcine coronary artery smooth muscle cells. Circ. Res. 102, 653–660 10.1161/CIRCRESAHA.107.170472 [DOI] [PubMed] [Google Scholar]
- Chen H., Kovar J., Sissons S., Cox K., Matter W., Chadwell F., Luan P., Vlahos C. J., Schutz- Geschwender A., Olive D. M. (2005). A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal. Biochem. 338, 136–142 10.1016/j.ab.2004.11.033 [DOI] [PubMed] [Google Scholar]
- Cooper C. D., Solan J. L., Dolejsi K. K., Lampe P. D. (2000). Analysis of connexin phosphorylation sites. Methods 20, 196–204 10.1006/meth.1999.0937 [DOI] [PubMed] [Google Scholar]
- Coutinho P., Qiu C., Frank S., Tamber K., Becker D. (2003). Dynamic changes in connexin expression correlate with key events in the wound healing process. Cell Biol. Int. 27, 525–541 10.1016/S1065-6995(03)00077-5 [DOI] [PubMed] [Google Scholar]
- Dang X., Jeyaraman M., Kardami E. (2006). Regulation of connexin-43- mediated growth inhibition by a phosphorylatable amino-acid is independent of gap junction-forming ability. Mol. Cell. Biochem. 289, 201–207 10.1007/s11010-006-9162-2 [DOI] [PubMed] [Google Scholar]
- Dey N. B., Foley K. F., Lincoln T. M., Dostmann W. R. (2005). Inhibition of cGMP dependent protein kinase reverses phenotypic modulation of vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 45, 404–413 10.1097/01.fjc.0000157455.38068.12 [DOI] [PubMed] [Google Scholar]
- Dostmann W. R., Tegge W., Frank R., Nickl C. K., Taylor M. S., Brayden J. E. (2002). Exploring the mechanisms of vascular smooth muscle tone with highly specific, membrane-permeable inhibitors of cyclic GMP-dependent protein kinase Iα. Pharmacol. Ther. 93, 203–215 10.1016/S0163-7258(02)00189-4 [DOI] [PubMed] [Google Scholar]
- Durante W., Schini V. B., Catovsky S., Kroll M. H., Vanhoutte P. M., Schafer A. I. (1993). Plasmin potentiates induction of nitric oxide synthase in vascular smooth muscle cells. Am. J. Physiol. 264, H617–H624 [DOI] [PubMed] [Google Scholar]
- Evans W. H., Martin P. E. (2002). Gap junctions: structure and function. Mol. Membr. Biol. 19, 121–136 10.1080/09687680210139839 [DOI] [PubMed] [Google Scholar]
- Figueroa X. F., Duling B. R. (2009). Gap junctions in the control of vascular function. Antioxid. Redox Signal. 11, 251–266 10.1089/ars.2008.2117 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Figueroa X. F., Isakson B. E., Duling B. R. (2006). Vascular gap junctions in hypertension. Hypertension 48, 804–811 10.1161/01.HYP.0000242483.03361.da [DOI] [PubMed] [Google Scholar]
- Giordano A., Romano S., Mallardo M., D’Angelillo A., Calí G., Corcione N., Ferraro P., Romano M. F. (2008). FK506 can activate transforming growth factor-β signalling in vascular smooth muscle cells and promote proliferation. Cardiovasc. Res. 79, 519–526 10.1093/cvr/cvn079 [DOI] [PubMed] [Google Scholar]
- Goodwin J. S., Kenworthy A. K. (2005). Photobleaching approaches to investigate diffusional mobility and trafficking of Ras in living cells. Methods 37, 154–164 10.1016/j.ymeth.2005.05.013 [DOI] [PubMed] [Google Scholar]
- Haas T. L., Duling B. R. (1997). Morphology favors an endothelial cell pathway for longitudinal conduction within arterioles. Microvasc. Res. 53, 113–120 10.1006/mvre.1996.1999 [DOI] [PubMed] [Google Scholar]
- Haefliger J. A., Nicod P., Meda P. (2004). Contribution of connexins to the function of the vascular wall. Cardiovasc. Res. 62, 345–356 10.1016/j.cardiores.2003.11.015 [DOI] [PubMed] [Google Scholar]
- Huard C., Druesne N., Guyonnet D., Thomas M., Pagniez A., Le Bon A. M., Martel P., Chaumontet C. (2004). Diallyl disulfide (DADS) enhances gap-junctional intercellular communication by both direct and indirect mechanisms in rat liver cells. Carcinogenesis 25, 91–98 10.1093/carcin/bgg182 [DOI] [PubMed] [Google Scholar]
- Indolfi C., Di Lorenzo E., Rapacciuolo A., Stingone A. M., Stabile E., Leccia A., Torella D., Caputo R., Ciardiello F., Tortora G., Chiariello M. (2000). 8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. J. Am. Coll. Cardiol. 36, 288–293 10.1016/S0735-1097(00)00679-3 [DOI] [PubMed] [Google Scholar]
- Isakson B. E., Damon D. N., Day K. H., Liao Y., Duling B. R. (2006). Connexin40 and connexin43 in mouse aortic endothelium: evidence for coordinated regulation. Am. J. Physiol. Heart Circ. Physiol. 290, H1199–H1205 10.1152/ajpheart.00945.2005 [DOI] [PubMed] [Google Scholar]
- Jara P. I., Boric M. P., Saez J. C. (1995). Leukocytes express connexin 43 after activation with lipopolysaccharide and appear to form gap junctions with endothelial cells after ischemia-reperfusion. Proc. Natl. Acad. Sci. U.S.A. 92, 7011–7015 10.1073/pnas.92.15.7011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Johnstone S., Isakson B., Locke D. (2009). Biological and biophysical properties of vascular connexin channels. Int. Rev. Cell Mol. Biol. 278, 69–118 10.1016/S1937-6448(09)78002-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Joshi C. N., Martin D. N., Fox J. C., Mendelev N. N., Brown T. A., Tulis D. A. (2011). The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the PKA and PKG pathways. J. Pharmacol. Exp. Ther. 339, 394–402 10.1124/jpet.111.183400 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kanemitsu M. Y., Jiang W., Eckhart W. (1998). Cdc2-mediated phosphorylation of the gap junction protein, connexin43, during mitosis. Cell Growth Differ. 9, 13–21 [PubMed] [Google Scholar]
- Knowles L. M., Milner J. A. (2000). Allyl sulfides modify cell growth. Drug Metabol. Drug. Interact. 17, 81–107 10.1515/DMDI.2000.17.1-4.81 [DOI] [PubMed] [Google Scholar]
- Koo S. K., Kim D. Y., Park S. D., Kang K. W., Joe C. O. (1997). PKC phosphorylation disrupts gap junctional communication at G0/S phase in clone 9 cells. Mol. Cell. Biochem. 167, 41–49 10.1023/A:1006831114120 [DOI] [PubMed] [Google Scholar]
- Kumar N. M., Gilula N. B. (1996). The gap junction communication channel. Cell 84, 381–388 10.1016/S0092-8674(00)81282-9 [DOI] [PubMed] [Google Scholar]
- Kurjiaka D. T., Steele T. D., Olsen M. V., Burt J. M. (1998). Gap junction permeability is diminished in proliferating vascular smooth muscle cells. Am. J. Physiol. 275, C1674–C1682 [DOI] [PubMed] [Google Scholar]
- Kwak B. R., Jongsma H. J. (1996). Regulation of cardiac gap junction channel permeability and conductance by several phosphorylating conditions. Mol. Cell. Biochem. 157, 93–99 10.1007/BF00227885 [DOI] [PubMed] [Google Scholar]
- Kwak B. R., Mulhaupt F., Veillard N., Gros D. B., Mach F. (2002). Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 22, 225–230 10.1161/hq0102.104125 [DOI] [PubMed] [Google Scholar]
- Kwak B. R., Van Veen T. A. B., Analbers L. J. S., Jongsma H. J. (1995). TPA increases conductance but decreases permeability in neonatal rat cardiomyocyte gap junction channels. Exp. Cell Res. 220, 456–463 10.1006/excr.1995.1337 [DOI] [PubMed] [Google Scholar]
- Laird D. W. (2005). Connexin phosphorylation as a regulatory event linked to gap junction internalization and degradation. Biochim. Biophys. Acta 1711, 172–182 10.1016/j.bbamem.2004.09.009 [DOI] [PubMed] [Google Scholar]
- Laird D. W., Puranam K. L., Revel J. P. (1991). Turnover and phosphorylation dynamics of connexin43 gap junction protein in cultured cardiac myocytes. Biochem. J. 273, 67–72 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lampe P. D., Kurata W. E., Warn-Cramer B., Lau A. F. (1998). Formation of a distinct connexin43 phosphoisoform in mitotic cells is dependent upon p34cdc2 kinase. J. Cell. Sci. 111, 833–841 [DOI] [PubMed] [Google Scholar]
- Lampe P. D., Lau A. F. (2000). Regulation of gap junctions by phosphorylation of connexins. Arch. Biochem. Biophys. 384, 205–215 10.1006/abbi.2000.2131 [DOI] [PubMed] [Google Scholar]
- Lampe P. D., Lau A. F. (2004). The effects of connexin phosphorylation on gap junctional communication. Int. J. Biochem. Cell Biol. 36, 1171–1186 10.1016/S1357-2725(03)00264-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lampe P. D., TenBroek E. M., Burt J. M., Kurata W. E., Johnson R. G., Lau A. F. (2000). Phosphorylation of connexin43 on serine368 by protein kinase c regulates gap junctional communication. J. Cell Biol. 149, 1503–1512 10.1083/jcb.149.7.1503 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liao Y., Regan C. P., Manabe I., Owens G. K., Day K. H., Damon D. N., Duling B. R. (2007). Smooth muscle-targeted knockout of connexin43 enhances neointimal formation in response to vascular injury. Arterioscler. Thromb. Vasc. Biol. 27, 1037–1042 10.1161/ATVBAHA.106.137182 [DOI] [PubMed] [Google Scholar]
- Lincoln T. M., Wu X., Sellak H., Dey N., Choi C. S. (2006). Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase. Front. Biosci. 11, 356–367 10.2741/1803 [DOI] [PubMed] [Google Scholar]
- Little T. L., Beyer E. C., Duling B. R. (1995). Connexin 43 and connexin 40 gap junctional proteins are present in arteriolar smooth muscle and endothelium in vivo. Am. J. Physiol. 268, H729–H739 [DOI] [PubMed] [Google Scholar]
- Liu X. M., Peyton K. J., Mendelev N. N., Wang H., Tulis D. A., Durante W. (2009). YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells. Mol. Pharmacol. 75, 208–217 10.1124/mol.108.051060 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maurice D. H., Haslam R. J. (1990). Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylatecyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol. 37, 671–681 [PubMed] [Google Scholar]
- Mendelev N. N., Williams V. S., Tulis D. A. (2009). Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 53, 121–131 10.1097/FJC.0b013e31819715c4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Muller-Borer B. J., Cascio W. E., Anderson P. A. W., Snowwaert J. N., Frye J. R., Desai N., Bagnell C. R., Coleman W. B., Grisham J. W., Malouf N. N. (2004). Adult derived liver stem cells acquire a cardiac myocyte structural and functional phenotype in culture. Am. J. Pathol. 165, 135–145 10.1016/S0002-9440(10)63282-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nihei O. K., Fonseca P. C., Rubim N. M., Bonavita A. G., Lyra J. S., Neves-dos-Santos S., de Carvalho A. C., Spray D. C., Savino W., Alves L. A. (2010). Modulatory effects of cAMP and PKC activation on gap junctional intercellular communication among thymic epithelial cells. BMC Cell Biol. 11, 3 10.1186/1471-2121-11-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Norris R. P., Freudzon M., Mehlmann L. M., Cowan A. E., Simon A. M., Paul D. L., Lampe P. D., Jaffe L. A. (2008). Luteinizing hormone causes MAP kinase dependent phosphorylation and closure of connexin 43 gap junctions in mouse ovarian follicles: one of two paths to meiotic resumption. Development 135, 3229–3238 10.1242/dev.025494 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Paulson A. F., Lampe P. D., Meyer R. A., Atkinson M. A., Walseth T. F., Johnson R. G. (2000). Cyclic AMP and LDL trigger a rapid enhancement in gap junction assembly through a stimulation of connexin trafficking. J. Cell. Sci. 113, 3037–3049 [DOI] [PubMed] [Google Scholar]
- Polacek D., Bech F., McKinsey J. F., Davies P. F. (1997). Connexin43 gene expression in the rabbit arterial wall: effects of hypercholesterolemia, balloon injury and their combination. J. Vasc. Res. 34, 19–30 10.1159/000317488 [DOI] [PubMed] [Google Scholar]
- Reinhard M., Jarchau T., Walter U. (2001). Actin-based motility: stop and go with Ena/VASP proteins. Trends Biochem. Sci. 26, 243–249 10.1016/S0968-0004(00)01785-0 [DOI] [PubMed] [Google Scholar]
- Rivedal E., Opsahl H. (2001). Role of PKC and MAP kinase in EGF- and TPA-induced connexin43 phosphorylation and inhibition of gap junction intercellular communication in rat liver epithelial cells. Carcinogenesis 22, 1543–1550 10.1093/carcin/22.9.1543 [DOI] [PubMed] [Google Scholar]
- Ruch R. J., Trosko J. E., Madhukar B. V. (2001). Inhibition of connexin43 gap junctional intercellular communication by TPA requires ERK activation. J. Cell. Biochem. 83, 163–169 10.1002/jcb.1227 [DOI] [PubMed] [Google Scholar]
- Saitongdee P., Becker D. L., Milner P., Knight G. E., Burnstock G. (2004). Levels of gap junction proteins in coronary arterioles and aorta of hamsters exposed to the cold and during hibernation and arousal. J. Histochem. Cytochem. 52, 603–615 10.1177/002215540405200505 [DOI] [PubMed] [Google Scholar]
- Schaffer E. M., Liu J. Z., Green J., Dangler C. A., Milner J. A. (1996). Garlic and associated allyl sulfur compounds inhibit N-methyl-N-nitrosourea induced rat mammary carcinogenesis. Cancer Lett. 102, 199–204 10.1016/0304-3835(96)04160-2 [DOI] [PubMed] [Google Scholar]
- Schlegel N., Waschke J. (2009). VASP is involved in cAMP-mediated Rac 1 activation in microvascular endothelial cells. Am. J. Physiol. Cell Physiol. 296, C453–C462 10.1152/ajpcell.00360.2008 [DOI] [PubMed] [Google Scholar]
- Schmidt V. J., Wölfle S. E., Boettcher M., de Wit C. (2008). Gap junctions synchronize vascular tone within the microcirculation. Pharmacol. Rep. 60, 68–74 [PubMed] [Google Scholar]
- Shao Q., Wang H., McLachlan E., Veitch G. I., Laird D. W. (2005). Down-regulation of Cx43 by retroviral delivery of small interfering RNA promotes an aggressive breast cancer cell phenotype. Cancer Res. 65, 2705–2711 10.1158/0008-5472.CAN-04-2367 [DOI] [PubMed] [Google Scholar]
- Shen J., Wang L. H., Zheng L. R., Zhu J. H., Hu S. J. (2010). Lovastatin inhibits gap junctional communication in cultured aortic smooth muscle cells. J. Cardiovasc. Pharmacol. Ther. 15, 296–302 10.1177/1074248410373750 [DOI] [PubMed] [Google Scholar]
- Solan J. L., Fry M. D., TenBroek E. M., Lampe P. D. (2003). Connexin43 phosphorylation at S368 is acute during S and G2/M and in response to protein kinase C activation. J. Cell Sci. 116, 2203–2211 10.1242/jcs.00428 [DOI] [PubMed] [Google Scholar]
- Solan J. L., Lampe P. D. (2007). Key connexin 43 phosphorylation events regulate the gap junction life cycle. J. Membr. Biol. 217, 35–41 10.1007/s00232-007-9035-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- Touyz R. M., Schiffrin E. L. (1997). Growth factors mediate intracellular signaling in vascular smooth muscle cells through protein kinase C-linked pathways. Hypertension 30, 1440–1447 10.1161/01.HYP.30.2.222 [DOI] [PubMed] [Google Scholar]
- Trosko J. E., Ruch R. J. (1998). Cell–cell communication in carcinogenesis. Front. Biosci. 15, D208–D236 [DOI] [PubMed] [Google Scholar]
- Wade M. H., Trosko J. E., Schindler M. (1986). A fluorescence photobleaching assay of gap junction-mediated communication between human cells. Science 232, 525–528 10.1126/science.3961495 [DOI] [PubMed] [Google Scholar]
- Wu Y., Bond M., Sala-Newby G., Newby A. (2006). Altered S-phase kinase-associated protein-2 levels are a major mediator of cyclic nucleotide-induced inhibition of vascular smooth muscle cell proliferation. Circ. Res. 98, 1141–1150 10.1161/01.RES.0000219905.16312.28 [DOI] [PubMed] [Google Scholar]
- Xie H., Laird D. W., Chang T. -H., Hu V. W. (1997). A mitosis-specific phosphorylation of the gap junction protein connexin43 in human vascular cells: Biochemical characterization and localization. J. Cell Biol. 137, 203–210 10.1083/jcb.137.1.203 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yamasaki H., Krutovskikh V., Mesnil M., Omori Y. (1996). Connexin genes and cell growth control. Arch. Toxicol. 18, 105–114 10.1007/978-3-642-61105-6_12 [DOI] [PubMed] [Google Scholar]
- Yamasaki H., Naus C. C. G. (1996). Role of connexin genes in growth control. Carcinogenesis 17, 1199–1213 10.1093/carcin/17.6.1199 [DOI] [PubMed] [Google Scholar]
- Yao J., Hiramatsu N., Zhu Y., Morioka T., Takeda M., Oite T., Kitamura M. (2005). Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells. J. Am. Soc. Nephrol. 16, 58–67 10.1681/ASN.2004110991 [DOI] [PubMed] [Google Scholar]
- Yeh H. I., Lupu F., Dupont E., Severs N. J. (1997). Upregulation of connexin43 gap junctions between smooth muscle cells after balloon catheter injury in the rat carotid artery. Arterioscler. Thromb. Vasc. Biol. 17, 3174–3184 10.1161/01.ATV.17.11.3174 [DOI] [PubMed] [Google Scholar]
- Yun S. P., Ryu J. M., Park J. H., Kim M. O., Lee J. H., Han H. J. (2012). Prostaglandin E2 maintains mouse ESC undifferentiated state through regulation of connexin 31, -43 and -45 expression: Involvement of glycogen synthase kinase 3β/β-catenin. Biol. Cell. [Epub ahead of print]. 10.1111/boc.201100032 [DOI] [PubMed] [Google Scholar]
- Zhang W., DeMattia J. A., Song H., Couldwell W. T. (2003). Communication between malignant glioma cells and vascular endothelial cells through gap junctions. J. Neurosurg. 98, 846–853 10.3171/jns.2003.98.4.0846 [DOI] [PubMed] [Google Scholar]
- Zhang Y. W., Wen J., Xiao J. B., Talbot S. G., Li G. C., Xu M. (2006). Induction of apoptosis and transient increase of phosphorylated MAPKs by diallyl disulfide treatment in human nasopharyngeal carcinoma CNE2 cells. Arch. Pharm. Res. 29, 1125–1131 10.1007/BF02969299 [DOI] [PubMed] [Google Scholar]